People
Possibly reflecting the current Bear market, Berkshire Hathaway has walked away from its stake in both AbbVie and BMS.
The current president, CEO and board member, Keith Kendall, is departing Aquestive. He will be replaced by Daniel Barber, its current chief operating officer.
CRISPR Therapeutics tapped Amgen veteran Phuong Khanh (P.K.) Morrow, M.D., FACP, as its new chief medical officer.
During the past several years, data generation, data mining and analytics have progressed to the point that it is now possible to bring precision medicine to psychiatry.
Agios Pharmaceuticals is cutting its staff numbers by 50 as part of plans to lay low on exploratory research efforts to focus on the success of late-stage initiatives.
Clay Siegall resigned his role as president, CEO and a member of the board of directors of Seagen following domestic violence allegations. Roger Dansey will serve as interim CEO.
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
Dr. Terry Fry, M.D., a leader in chimeric antigen receptor T-cell (CAR-T) therapies and senior vice president, head of T-cell therapeutics at Sana Biotechnology, will be heading the newly created Gates Institute.
Police documents reveal a May 2 dated TRO against Siegall concerning a fourth degree domestic violence gross misdemeanor charge.
Usama Malik, the former chief financial officer of Immunomedics, has been indicted for insider trading, five months after the U.S. Securities and Exchange Commission leveled charges.
PRESS RELEASES